In the INSIGHT 2 trial, an open-label 2-arm phase 2 study, patients with advanced EGFR mutated NSCLC with MET-amp after progression on first-line osimertinib received tepotinib 500 mg (450 mg active moiety) + osimertinib 80 mg once daily. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.